Quick Answer
Protalix BioTherapeutics, Inc. reported Shares Outstanding of 80.43 million shares for fiscal year 2025.
Protalix BioTherapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 80.43M | +6.0% |
| 2024 | 75.85M | +4.0% |
| 2023 | 72.95M | +35.6% |
| 2022 | 53.79M | +18.1% |
| 2021 | 45.56M | +31.0% |
| 2020 | 34.77M | +134.3% |
| 2019 | 14.84M | +0.0% |
| 2018 | 14.84M | -89.7% |
| 2017 | 143.73M | +15.8% |
| 2016 | 124.13M | +24.4% |
| 2015 | 99.80M | +6.6% |
| 2014 | 93.60M | +0.1% |
| 2013 | 93.55M | +0.1% |
| 2012 | 93.49M | +9.2% |
| 2011 | 85.63M | +5.4% |
| 2010 | 81.25M | — |
- Protalix BioTherapeutics, Inc. showed an increase of +6.0% in Shares Outstanding compared to the prior fiscal year.
- Over the 2010–2025 period, Protalix BioTherapeutics, Inc.’s shares outstanding has declined by 1.0% (from 81.25 million shares to 80.43 million shares).
- The most recent figure is from Protalix BioTherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: